Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03425643
Title Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Cisplatin + Gemcitabine + Pembrolizumab

Pembrolizumab

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.